Corbus Advances CRB-913 Toward Phase 2 in Obesity
NORWOOD, Mass. — September 14, 2026 Corbus Pharmaceuticals Holdings, Inc. announced positive topline results from its CANYON-1 Phase 1b...
Obesity
Advertisement
MetaVia Reports Preclinical Data on DA-1726 Waist Reduction
Cambridge, Massachusetts, September 9, 2026 MetaVia Inc., a clinical-stage biotechnology company focused on cardiometabolic diseases, has reported new preclinical...
Structure Therapeutics Reports Positive Oral Weight-Loss Data
SAN FRANCISCO — September 8, 2026 Structure Therapeutics reported positive clinical data across its two lead oral small-molecule programs...
Moonwalk Biosciences Raises $70 Million Series B
SOUTH SAN FRANCISCO and SAN DIEGO — September 8, 2026 Moonwalk Biosciences announced the closing of an oversubscribed $70...
Ascletis Begins U.S. Phase 1 Study of ASC36
Hong Kong, September 8, 2026 Ascletis Pharma Inc. has announced the initiation of a U.S. Phase 1 clinical trial...
Advertisements
Eli Lilly Links Zepbound to Lower Healthcare Costs
Zepbound Use Associated With Lower Healthcare Costs INDIANAPOLIS, Aug. 26, 2026 — Eli Lilly and Company announced new real-world...
Mend Expands Mend Well Into Chronic Care Management
New York, NY – August 25, 2026 Mend announced the expansion of Mend Well, its clinically supported remote-care program,...
Enveda Reports Positive Phase 1 Results for ENV-308
BOULDER, Colo., August 18, 2026 Enveda announced positive Phase 1 results for ENV-308, an investigational oral medicine designed from...
Kedrion Extends U.S. Agreement to Support GAMMAKED Access
FORT LEE, N.J., August 18, 2026 Kedrion Biopharma announced an extension of its U.S. agreement with Grifols to continue...
Amygdala Advances ANS-858 After FDA IND Clearance
PALO ALTO, Calif., August 18, 2026 Amygdala Neurosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
